Gulf War Illness

Prevalence and Characteristics

• Approximately 25-49.5% of Gulf War veterans are affected by Gulf War Illness (GWI), also known as Chronic Multisymptom Illness (CMI), which is characterized by multiple poorly understood symptoms affecting various body systems, according to the VA/DoD Clinical Practice Guideline 1

Treatment Approach

• A holistic approach that emphasizes patient-centered care, shared decision-making, and team-based approaches is recommended to improve quality of life and function for patients with GWI, as suggested by the VA/DoD Clinical Practice Guideline 1
• The management of chronic pain and Gulf War syndrome requires a comprehensive approach, including non-pharmacological and pharmacological interventions, as recommended by the American College of Physicians and the Mayo Clinic 2, 1

Non-Pharmacological Interventions

• Cognitive-behavioral therapy (CBT) combined with exercise is the most effective treatment for Gulf War syndrome, showing significant improvement in key symptoms, including cognitive functioning and fatigue, according to the Mayo Clinic Proceedings 1
• The American College of Physicians recommends CBT as a primary treatment, with strong evidence supporting its use, showing higher odds of improved health function compared to usual care 1
• Mindfulness-Based Therapies have been shown to reduce functional impairment in patients with symptoms similar to those in CMI, as reported by the Mayo Clinic Proceedings 1
• Aerobic Exercise has demonstrated benefits when used alone or in combination with CBT, according to the Mayo Clinic Proceedings 1
• Physical Activity Programs have been shown to improve aerobic capacity and reduce fatigue, as reported by the Mayo Clinic Proceedings 1
• Exercise and physical therapy are recommended as first-line treatments for chronic pain, with a strength of evidence supported by multiple studies 2, 3, 4

Pharmacological Interventions

• Nonopioid pharmacologic therapies, such as NSAIDs, acetaminophen, anticonvulsants, and SNRIs, may be used to manage chronic pain, with the goal of minimizing opioid use, as recommended by the American College of Physicians and the Mayo Clinic 2, 5
• Opioids should NOT be used for long-term management of chronic pain in CMI, as recommended by both the Mayo Clinic Proceedings and the Annals of the Rheumatic Diseases 1, 6
• Opioids may be appropriate in specific circumstances, such as when expected benefits for both pain and function outweigh risks, or when alternative treatments have not provided adequate analgesia, as suggested by the American College of Physicians and the Centers for Disease Control and Prevention (CDC) 2, 7, 8
• The following medications have specific considerations:

• Rifaximin may be considered for a 14-day course for patients with IBS-like symptoms without constipation, according to the Mayo Clinic Proceedings 1

Fatigue Management

• The Mayo Clinic Proceedings recommends against using stimulants for fatigue management due to potential harms outweighing benefits 1
• The Mayo Clinic Proceedings also recommends against using KPAX002 (methylphenidate hydrochloride plus supplement) as it did not significantly improve fatigue-related symptoms compared to placebo 1

Comorbid Conditions

• The Mayo Clinic Proceedings recommends treating comorbid conditions such as PTSD, depression, and other physical health problems, as proper treatment can improve overall symptoms 1
• Opioids should not be considered first-line or routine therapy for chronic pain outside of active cancer, palliative, and end-of-life care, given their small to moderate short-term benefits, uncertain long-term benefits, and potential for serious harms, as recommended by the American Medical Association and the Centers for Disease Control and Prevention (CDC) 2, 9

Safety Considerations

• Side effects are common, with 90% of patients experiencing at least one opioid-related adverse event, highlighting the need for careful monitoring and risk assessment, as recommended by the CDC and the American Medical Association 10, 2
• Concurrent benzodiazepine use should be avoided whenever possible due to increased overdose risk, and dose escalation without benefit should be avoided, as recommended by the CDC and the FDA 2
• Patients with psychiatric comorbidities, such as bipolar disorder, are at increased risk of misuse, and age 69 or older increases the risk of adverse effects from opioid therapy, as recommended by the CDC and the National Comprehensive Cancer Network 2, 11
• The patient should be monitored for serotonin syndrome with SNRI addition, and for sedation with increased gabapentin, with a high strength of evidence supporting the importance of monitoring, as recommended by the National Comprehensive Cancer Network 12